

- 10:30 - 10:40 **Welcome from LS Academy Staff**
- 10:40 - 10:45 **Welcome from the scientific board**
- 10:45 - 11:05 **News from the EMA in pharmacovigilance**
Nicole Bick – *Safety and Pharmacovigilance Expert*
- 11:05 - 11:25 **Data, information, insights: A tailored PV approach (industry perspective)**
Ulrich Vogel – *Head of Strategic Data Analysis at Boehringer Ingelheim*
- 11:25 - 11:40 **Virtual Coffee Break**
- 11:40 - 12:00 **Artificial intelligence in pharmacovigilance: gains and risks**
Eva-Maria Westphal – *Associate Director and Engagement Manager (Pharmacovigilance), Global Tech Solutions at IQVIA*
- 12:00 - 12:30 **Q&A Session related to morning presentations**
- 12:30 - 12:50 **Risk Minimisation Measures (Educational materials and “Rote Hand Brief”): Status Quo and challenges from an industry perspective - First part**
Boris Thurisch – *Managing Director Medicine and Science, Head of the Pharmacovigilance at German Pharmaceutical Industry Association*
- 12:50 - 12:55 **Morning conclusion**
- 12:55 - 14:30 **Lunch Break**
- 14:30 - 14:50 **Risk Minimisation Measures (Educational materials and “Rote Hand Brief”): Status Quo and challenges from an industry perspective - Second part**
Boris Thurisch – *Managing Director Medicine and Science, Head of the Pharmacovigilance at German Pharmaceutical Industry Association*
- 14:50 - 15:10 **Measurement of effectiveness of risk minimization measures: challenges from an industry perspective**
Monika Borchert – *Deputy EU-QPPV Head at Novartis*
- 15:10 - 15:25 **Virtual Coffee Break**
- 15:25 - 15:45 **Safety concerns and impact of GVP module V revision 2: challenges from an industry perspective**
Tiziana von Bruchhausen – *Senior Pharmacovigilance Writer at Boehringer Ingelheim*
- 15:45 - 16:05 **News from the Harmonisation of RMP Project (HaRP)**
Nicole Bick – *Safety and Pharmacovigilance Expert*
- 16:05 - 16:35 **Q&A Session related to afternoon presentations**
- 16:35 - 16:40 **Conclusions**